WallStSmart

Bloom Energy Corp (BE)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Vertex Pharmaceuticals Inc generates 399% more annual revenue ($12.22B vs $2.45B). VRTX leads profitability with a 35.5% profit margin vs 0.3%. BE appears more attractively valued with a PEG of 1.53. VRTX earns a higher WallStSmart Score of 66/100 (B-).

BE

Hold

40

out of 100

Grade: D

Growth: 6.7Profit: 5.0Value: 4.7Quality: 5.3
Piotroski: 3/9Altman Z: -0.52

VRTX

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 6.7Quality: 8.0
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BE.

VRTXUndervalued (+56.6%)

Margin of Safety

+56.6%

Fair Value

$989.67

Current Price

$448.29

$541.38 discount

UndervaluedFair: $989.67Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BE2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
130.4%10/10

Revenue surging 130.4% year-over-year

Market CapQuality
$73.57B9/10

Large-cap with strong market position

VRTX6 strengths · Avg: 9.7/10
Profit MarginProfitability
35.5%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability
38.1%10/10

Strong operational efficiency at 38.1%

EPS GrowthGrowth
61.4%10/10

Earnings expanding 61.4% YoY

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$107.87B9/10

Large-cap with strong market position

Return on EquityProfitability
24.2%9/10

Every $100 of equity generates 24 in profit

Areas to Watch

BE4 concerns · Avg: 3.3/10
PEG RatioValuation
1.534/10

Expensive relative to growth rate

Return on EquityProfitability
1.3%3/10

ROE of 1.3% — below average capital efficiency

Profit MarginProfitability
0.3%3/10

0.3% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
2.104/10

Expensive relative to growth rate

P/E RatioValuation
25.3x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BE

The strongest argument for BE centers on Revenue Growth, Market Cap. Revenue growth of 130.4% demonstrates continued momentum.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.

Bear Case : BE

The primary concerns for BE are PEG Ratio, Return on Equity, Profit Margin. Thin 0.3% margins leave little buffer for downturns.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

BE profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.

BE carries more volatility with a beta of 3.83 — expect wider price swings.

BE is growing revenue faster at 130.4% — sustainability is the question.

VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (66/100 vs 40/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bloom Energy Corp

INDUSTRIALS · ELECTRICAL EQUIPMENT & PARTS · USA

Bloom Energy Corporation designs, manufactures and sells solid oxide fuel cell systems for on-site power generation in the United States, Japan, China, India, and the Republic of Korea. The company is headquartered in San Jose, California.

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?